Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Prevention of cytomegalovirus (CMV) infection in kidney transplant recipients (KTRs) is essential in post-transplant management, as it negatively affects graft function and patient survival. CMV infection is also linked to indirect effects such as graft dysfunction, acute T cellmediated rejection (AR), and increased susceptibility to other opportunistic infections. Current preventive strategies include universal prophylaxis with valganciclovir (VGC) or preemptive therapy (PT) based on PCR monitoring, both effective but debated in their optimal use, especially in intermediate-risk patients (R+/D+ or R+/D−) receiving basiliximab (BSL), where efficacy, safety, and cost must be balanced.
Between March 1, 2024, and July 31, 2025, an open-label, randomized, single-center clinical trial was conducted with a 12-month follow-up, including 52 living-related KTRs. Participants were assigned 1:1 using a random number table. Group 1 (control) received antiviral prophylaxis with VGC, while Group 2 was managed with a PT strategy. Both groups received BSL-based induction immunosuppression. In the PT group, quantitative serum CMV PCR was performed every 15 days for the first 3 months; afterward, both groups underwent monthly monitoring through month 12. Clinical, biochemical, and virological data were collected at each visit, along with adverse events, CMV infection, CMV disease, hematological changes, and AR episodes.
Five CMV infections were recorded during follow-up (9.6% overall): two cases (8%) in the PT group and three (12%) in the prophylaxis group. The difference was not significant (χ²=0.222, p=0.64; HR=0.68,95% CI0.097–4.1),indicating PT did not increase CMV risk. No significant biochemical differences were observed at baseline or follow-up, and viremia episodes were transient, without clinical deterioration or progression to CMV disease. Adverse events and graft-related complications were comparable between groups
Both universal VGC prophylaxis and PCR-guided PT were safe and effective for CMV prevention in intermediate-risk living-donor KTRs. No significant differences were found in infection incidence, CMV-free survival, or clinical outcomes. These results support adapting preventive strategies to available resources and diagnostic capacity. In settings with reliable virological monitoring, PT may be a cost-effective alternative, reducing unnecessary antiviral exposure without compromising efficacy.
